... Furthermore, with the advent of new DES systems, it is important to elucidate any differences in efficacy and safety when utilizing the currently availab l e DESs. Therefore, we report the ... patients in the ZES treated group were prematurely taken off their antiplatelet therapy and this likely played a role in the observed MACE events. Also noteworthy was the observation that, the lesion ... 12.8%, at the end of the two-year period. In our trial, however, the incidence of MACE in the ZES treated group was 10% at the end of the two year follow-up (Table 4). Additionally, the inci-dence...